Department of Biomedical Engineering, University of Wisconsin-Madison, WI, USA; Morgridge Institute for Research, Madison, WI, USA.
Morgridge Institute for Research, Madison, WI, USA.
Acta Biomater. 2019 Sep 1;95:371-381. doi: 10.1016/j.actbio.2019.07.047. Epub 2019 Jul 27.
Human-induced pluripotent stem cell (hiPSC)-derived hepatocytes (iHEP) offer an attractive alternative to primary human hepatocytes (PHH) for drug toxicity studies, as PHHs are limited in supply, vary in their metabolic activity between donors, and rapidly lose their functionality in vitro. However, one of the major drawbacks with iHEP cells in drug safety studies is their decreased phenotypic maturity, with lower liver specific enzyme activity compared with that of PHH. Here we evaluated the effects of 3D culture and non-parenchymal cells on the maturation of iHEPs. We describe a serum-free, chemically defined 3D in vitro model using iHEP cells, which is compatible with automation and conventional assay plates. The iHEP cells cultured in this model form polarized aggregates with functional bile canaliculi and strongly increased expression of albumin, urea and genes encoding phase I and II drug metabolism enzymes and bile transporters. Cytochrome P450-mediated metabolism is significantly higher in 3D iHEP aggregates compared to 2D iHEP culture. Furthermore, addition of human liver sinusoidal endothelial cells (sECs) and iPS-derived endothelial cells (iECs) improved mature hepatocyte function and CYP450 enzyme activity. Also, ECs formed endothelial networks within the hepatic 3D cultures, mimicking aspects of an in vivo architecture. Collectively, these results suggest that the iHEP/EC aggregates described here may have the potential to be used for many applications, including as an in vitro model to study liver diseases associated with sinusoidal endothelial cells. STATEMENT OF SIGNIFICANCE: iPS-derived hepatocytes provide an inexhaustible source of cells for drug screening, toxicology studies and cell-based therapies, but lack mature phenotype of adult primary human hepatocytes (PHH). Herein, we show that 3D culture of iPS-derived hepatocytes and their co-culture with human sinusoidal endothelial cells (sECs) to improve their maturity.
人诱导多能干细胞(hiPSC)衍生的肝细胞(iHEP)为药物毒性研究提供了一种有吸引力的替代原代人肝细胞(PHH)的方法,因为 PHH 供应有限,供体之间的代谢活性不同,并且在体外迅速失去功能。然而,iHEP 细胞在药物安全性研究中的一个主要缺点是其表型成熟度降低,与 PHH 相比,肝脏特异性酶活性较低。在这里,我们评估了 3D 培养和非实质细胞对 iHEP 成熟的影响。我们描述了一种使用 iHEP 细胞的无血清、化学定义的 3D 体外模型,该模型与自动化和常规测定板兼容。在该模型中培养的 iHEP 细胞形成具有功能胆小管的极化聚集物,并强烈增加白蛋白、尿素和编码 I 相和 II 相药物代谢酶和胆汁转运体的基因的表达。与 2D iHEP 培养相比,3D iHEP 聚集物中的细胞色素 P450 介导的代谢显著升高。此外,添加人肝窦内皮细胞(sEC)和 iPS 衍生的内皮细胞(iEC)可改善成熟肝细胞功能和 CYP450 酶活性。此外,EC 在肝 3D 培养物中形成内皮网络,模拟体内结构的某些方面。总之,这些结果表明,这里描述的 iHEP/EC 聚集物可能具有用于许多应用的潜力,包括作为研究与窦内皮细胞相关的肝脏疾病的体外模型。
iPS 衍生的肝细胞为药物筛选、毒理学研究和基于细胞的治疗提供了一种取之不尽的细胞来源,但缺乏成年原代人肝细胞(PHH)的成熟表型。在此,我们展示了 iPS 衍生的肝细胞的 3D 培养及其与人窦内皮细胞(sEC)的共培养以提高其成熟度。